Radiation therapy of acromegaly
- PMID: 1521519
Radiation therapy of acromegaly
Abstract
Conventional megavoltage irradiation of GH-secreting tumors has predictable effects on tumor mass, GH, and pituitary function. 1. Further growth of the tumor is prevented in more than 99% of patients, with only a fraction of a percent of patients requiring subsequent surgery for tumor mass effects. 2. GH falls predictably with time. By 2 years GH falls by about 50% from the baseline level, and by 5 years by about 75% from the baseline level. The initial GH elevation and the size and erosive features of the sella turcica do not affect the percent decrease in GH from the baseline elevation. 3. With prolonged follow-up, further decrease in GH is seen at 10 and 15 years, with the fraction of surviving patients achieving GH levels less than 5 ng/mL approaching 90% after 15 years in our experience. Gender, previous surgery, and hyperprolactinemia do not seem to affect the response to treatment. Patients with initial GH greater than 100 ng/mL are significantly less likely to achieve GH values less than 5 ng/mL during long-term follow-up. 4. Hypopituitarism is a predictable outcome of treatment, is delayed, and may be more likely in patients who have had surgery prior to irradiation. There is no evidence that this complication is more common in patients with acromegaly than in patients with other pituitary adenomas receiving similar treatment. 5. Vision loss due to megavoltage irradiation--using modern techniques and limiting the total dose to 4680 rad given in 25 fractions over 35 days, with individual fractions not exceeding 180 rad--is extremely rare. The reported cases have occurred almost entirely in patients who have received larger doses or higher fractional doses. The theory that patients with acromegaly are prone to radiation-induced injury to the CNS and optic nerves and chiasm because of small vessel disease is not supported by a review of the reported cases. 6. Brain necrosis and secondary neoplasms induced by irradiation are extremely rare. 7. Although anecdotal evidence raises the question of changes in intellectual function following irradiation, this has not been studied in adults receiving pituitary irradiation.
Similar articles
-
Reevaluation of conventional pituitary irradiation in the therapy of acromegaly.Pituitary. 1999 Jun;2(1):55-62. doi: 10.1023/a:1009969921497. Pituitary. 1999. PMID: 11081173 Review.
-
The long-term efficacy of conventional radiotherapy in patients with GH-secreting pituitary adenomas.Clin Endocrinol (Oxf). 2005 Feb;62(2):210-6. doi: 10.1111/j.1365-2265.2005.02199.x. Clin Endocrinol (Oxf). 2005. PMID: 15670198
-
A prospective analysis of 151 cases of patients with acromegaly operated by one neurosurgeon: a follow-up of more than 23 years.Surg Neurol. 2006 Jul;66(1):26-31; discussion 31. doi: 10.1016/j.surneu.2005.11.063. Surg Neurol. 2006. PMID: 16793431
-
Fractionated stereotactic conformal radiotherapy for secreting and nonsecreting pituitary adenomas.Clin Endocrinol (Oxf). 2006 May;64(5):542-8. doi: 10.1111/j.1365-2265.2006.02506.x. Clin Endocrinol (Oxf). 2006. PMID: 16649974
-
Is there still a role for radiotherapy in acromegaly?Neuroendocrinology. 2006;83(3-4):269-73. doi: 10.1159/000095538. Neuroendocrinology. 2006. PMID: 17047393 Review.
Cited by
-
Acromegaly: treatment after 100 years.BMJ. 1993 Dec 11;307(6918):1505-6. doi: 10.1136/bmj.307.6918.1505. BMJ. 1993. PMID: 8274912 Free PMC article. No abstract available.
-
Pharmacotherapy or surgery as primary treatment for acromegaly?Drugs Aging. 2000 Aug;17(2):81-92. doi: 10.2165/00002512-200017020-00001. Drugs Aging. 2000. PMID: 10984197 Review.
-
Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly.Pituitary. 2000 May;2(4):269-76. doi: 10.1023/a:1009961116472. Pituitary. 2000. PMID: 11081148 Clinical Trial.
-
Surgical management of acromegaly: Long term functional outcome analysis and assessment of recurrent/residual disease.Asian J Neurosurg. 2016 Jul-Sep;11(3):261-7. doi: 10.4103/1793-5482.145354. Asian J Neurosurg. 2016. PMID: 27366253 Free PMC article.
-
Reevaluation of conventional pituitary irradiation in the therapy of acromegaly.Pituitary. 1999 Jun;2(1):55-62. doi: 10.1023/a:1009969921497. Pituitary. 1999. PMID: 11081173 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical